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CCL17. These results suggest that M2
macrophages stimulated by RANKL/
RANK signaling might recruit Tregs into
the tumor microenvironment of EMPD,
which thereby induces an immunosup-
pressive microenvironment in EMPD.
Gordon and Martinez (2010)
classiﬁed the development of mono-
cytes into mature and fully activated
macrophages into three successive
stages. During the third phase of activa-
tion, macrophages reach a mature
functional phenotype in response to
microbial and opsonic stimuli such as
antibody complexes. In the present
study, macrophages induced by M-CSF
and IL-4 did not produce a substantial
amount of CCL17; however, when
these macrophages were stimulated by
sRANKL, they produced CCL17 in an
sRANKL dose-dependent manner.
These results suggest that sRANKL may
be another stimulus during the third
phase of macrophage activation.
Denosumab, a fully human mono-
clonal antibody for RANKL, is used
clinically to treat metastatic bone
tumors (Azim and Azim, 2013). Our
present study suggests that RANKL
targeting with denosumab can be used
in conjunction with the therapeutic
elimination of primary EMPD to pre-
vent local immunosuppression and
metastatic disease.
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TO THE EDITOR
Higher density of epidermal nerve ﬁbers
has been associated with itch sensitiza-
tion in the periphery, with nerve ﬁber
density being higher in atopic dermatitis
(AD) lesional skin than in normal skin
(Tominaga and Takamori, 2014). Con-
comitantly, the epidermal levels of the
nerve repulsion factor semaphorin 3A
(Sema3A) are lower in AD patients and
AD model NC/Nga mice than in controls
(Tominaga et al., 2008). Sema3A
replacement in AD model NC/Nga mice
normalized hyperinnervation, resulting in
the suppression of itching (Yamaguchi
et al., 2008; Negi et al., 2012).
To defend against pathogens, human
skin contains antimicrobial peptides,
including cathelicidins and β-defensins,
which are induced by inﬂammation
(Schauber and Gallo, 2008; Niyonsaba
et al., 2009). The induction of these
peptides, such as cathelicidin LL-37 and
human β-defensins, produced by epi-
dermal keratinocytes is impaired in
lesional skin in patients with AD,
explaining their frequent infections
(Ong et al., 2002; de Jongh et al.,Accepted article preview online 29 June 2015; published online 16 July 2015
Abbreviations: AD, atopic dermatitis; NHEK, normal human epidermal keratinocyte; P2X7R, P2X7
receptor; Sema3A, semaphorin 3A
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2005). However, the interrelationships
among Sema3A and antimicrobial
peptides are unclear. We therefore
investigated the effects of antimicrobial
peptides on Sema3A expression in
cultured normal human epidermal
keratinocytes (NHEKs), as well as the
signaling pathways involved in LL-37-
induced Sema3A expression.
NHEKs derived from adult epidermis
(Lonza, Basel, Switzerland) were
cultured in KBM-Gold (Lonza), a
serum-free medium containing a low
concentration (0.15mM) of calcium, at
37 °C with 5% CO2 and used within
three passages. LL-37 (L1LGDFFRKSKE-
KIGKEFKRIVQRIKDFLRNLVPRTES37)
was synthesized by the solid phase
method on a peptide synthesizer (model
PSSM-8; Shimadzu, Kyoto, Japan).
NHEKs were incubated with human β-
defensin-1–4 (Peptide Institute, Osaka,
Japan) or LL-37, and the levels of
Sema3A mRNA expression at different
time points were assessed by quantita-
tive real-time PCR using SYBR Premix Ex
Taq (TaKaRa, Kyoto, Japan) and the
primers 5′-ACCCAACTATCAATGGGTG
CCTTA-3′ (forward) and 5′-AACACTG
GATTGTACATGGCTGGA-3′ (reverse).
As controls, ribosome protein S18 mRNA
was ampliﬁed using the primers 5′-
TTTGCGAGTACTCAACACCAACATC-3′
(forward) and 5′-GAGCATATCTTCGGC
CCACAC-3′ (reverse).
Incubation with LL-37 for 48 hours
increased Sema3A expression, whereas
the individual human β-defensins had
little effect (Figure 1a). This LL-37-
induced Sema3A expression was dose-
and time dependent (Figure 1b). Further-
more, Sema3A protein levels measured
using ELISA kits (USCN Life Science,
Wuhan, China) were markedly higher in
the supernatants of NHEKs incubated
with LL-37 than in control supernatants
(Figure 1c).
LL-37 has been shown to activate rat
mast cells via G protein–coupled recep-
tors (Niyonsaba et al., 2001). Therefore,
the effects of cholera toxin (Wako Pure
Chemical Industries, Ltd. Osaka, Japan)
and pertussis toxin (Sigma-Aldrich, St
Louis, MO), inhibitors of the Gs and Gi
subfamilies of G protein α-subunit,
respectively, on Sema3A induction in
cultured NHEKs were analyzed. LL-37-
induced Sema3A expression was
completely inhibited by pretreatment
with pertussis toxin but not cholera
toxin (Figure 2a).
Activation of either mitogen-activated
protein kinase or phosphatidylinositol 3
kinase was found to be involved in the
LL-37 signaling pathway (Niyonsaba
et al., 2010). We therefore assessed the
effects of mitogen-activated protein
kinase and phosphatidylinositol 3 kinase
inhibitors on Sema3A induction in cul-
tured NHEKs. LL-37-induced Sema3A
expression was inhibited by pretreatment
with the extracellular signal-regulated
kinase 1/2 inhibitor PD98059 (Cell
Signaling Technology, Beverly, MA),
but not the phosphatidylinositol 3 kinase
inhibitor wortmannin (Sigma-Aldrich),
the p38 inhibitor SB203580 (Sigma-
Aldrich), and the c-Jun N-terminal kinase
inhibitor SP600125 (Calbiochem, Darm-
stadt, Germany; Figure 2b).
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Figure 1. Effects of antimicrobial peptides on Sema3A expression in cultured NHEKs. (a) NHEKs were
incubated with 10 μgml−1 hBD-1-4, LL-37, or medium alone (vehicle) for 3, 24, or 48 hours, and Sema3A
mRNA expression was assayed by quantitative real-time PCR. Sema3A mRNA levels were normalized
relative to those of RPS18. (b) Effects of LL-37 concentration on Sema3A mRNA expression. Values
represent fold changes compared with vehicle. LL-37 induced Sema3A expression dose- and time
dependently. (c) NHEKs were incubated with LL-37 for 48 hours, and the concentrations of Sema3A in the
cell-free supernatants were determined by ELISA. *Po0.05, ***Po0.0001 (two-way ANOVA followed by
Dunnett’s test), ###Po0.0001 (two-tailed Student’s t-test) compared with vehicle. All values represent the
mean± SD of 3–6 experiments. ANOVA, analysis of variance; hBD, human b defensin; NHEK, normal
human epidermal keratinocyte; RPS18, ribosome protein S18; Sema3A, semaphorin 3A.
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We next examined whether formyl
peptide receptor-like 1 and P2X7 recep-
tor (P2X7R), both candidate LL-37 rece-
ptors (Niyonsaba et al., 2009), are
involved in Sema3A induction in cul-
tured NHEKs. LL-37-induced Sema3A
expression was partially inhibited by
pretreatment with the P2X7R antagonist
BBG (Tokyo Chemical Industry, Tokyo,
Japan) but not by pretreatment with
the formyl peptide receptor-like 1
antagonist WRW4 (ABGENT, San
Diego, CA; Figure 2c).
Taken together, these ﬁndings
showed that the antimicrobial peptide
LL-37 markedly upregulated the expres-
sion of Sema3A mRNA and protein in
cultured human keratinocytes, whereas
the four human β-defensins were inac-
tive (Figure 1), indicating that LL-37 is
an endogenous inducer of Sema3A
expression in keratinocytes. Vitamin
D3, which increases cathelicidin
expression in keratinocytes (Schauber
and Gallo, 2008), might therefore also
drive the LL-37-Sema3A pathway.
We found that certain Gi-coupled
receptors are involved in Sema3A
induction (Figure 2a). Although LL-37
has been shown to activate G protein–
coupled receptors, such as formyl pep-
tide receptor-like 1, P2X7R, and Mas-
related G protein–coupled receptor X2
(MrgX2; Barlow et al., 2014), LL-37
receptors are less well-characterized in
human keratinocytes. We showed that
LL-37-induced Sema3A expression was
partly inhibited by a P2X7R antagonist,
but not by a formyl peptide receptor-
like 1 antagonist (Figure 2c), and that
MrgX2 mRNA expression was undetect-
able in NHEKs (Umehara et al.,
unpublished observation). These ﬁnd-
ings suggest that, although other recep-
tors may be involved in induction,
LL-37 activation of P2X7R is at least
partly involved in Sema3A induction in
keratinocytes. We also found that
LL-37-induced Sema3A expression was
completely inhibited by PD98059
(Figure 2b), indicating that extracellular
signal-regulated kinase 1/2 signaling
may be required for Sema3A induction.
In contrast, SP600125 increased rather
than inhibiting Sema3A expression
(Figure 2b), suggesting that c-Jun
N-terminal kinase signaling is involved
in the suppression of Sema3A expres-
sion in keratinocytes. Altered c-Jun
N-terminal kinase signaling might
reduce Sema3A production in AD.
Taken together, these ﬁndings suggest
that LL-37 may bind to certain Gi-
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Figure 2. Analysis of the signaling pathway involved in LL-37-induced Sema3A expression. NHEKs were pretreated with 100 μgml−1 cholera toxin (CT) (a),
200 ngml−1 pertussis toxin (PT) (a), 20 μM wortmannin (Wort.) (b), 10 μM SB203580 (SB) (b), 10 μM PD98059 (PD) (b), 10 μM SP600125 (SP) (b), 1 μM WRW4 (c),
1 μM BBG (c), or vehicle (− ) for 1 hour, followed by incubation for 24 hours with 20 μgml−1 LL-37, and Sema3A expression was assayed by quantitative real-time
PCR. Values represent fold changes compared with vehicle and the mean± SD of 4–6 experiments. **Po0.01 and ***Po0.001 compared with vehicle,
##Po0.01 compared with LL-37 alone (one-way ANOVA followed by Dunnett’s test). (d) Schematic diagram of the signaling pathway of LL-37-induced Sema3A
expression in NHEKs. ANOVA, analysis of variance; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; NHEK, normal human epidermal
keratinocyte; PI3K, phosphatidylinositol 3 kinase; Sema3A, semaphorin 3A.
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coupled receptors, including P2X7R,
activating the extracellular signal-
regulated kinase 1/2 signaling pathway,
and ﬁnally inducing Sema3A expres-
sion in human epidermal keratinocytes
(Figure 2d).
Although 70–90% of patients with
psoriasis also have pruritus, they are
rarely accompanied by intense itch as
in AD (Yosipovitch et al., 2000; Reich
and Szepietowski, 2007). We
previously showed that Sema3A
production was not reduced in the
epidermis of psoriatic patients with or
without itch (Taneda et al., 2011). In
contrast to AD, high levels of expression
of several antimicrobial peptides
including LL-37 were observed in psor-
iatic lesions (Ong et al., 2002; Nomura
et al., 2003), suggesting that epidermal
Sema3A expression is not reduced in
these patients. These ﬁndings suggest
that LL-37 may restore Sema3A produc-
tion in keratinocytes of certain patholo-
gical conditions such as psoriasis and
that the decreased epidermal Sema3A
production in AD lesional skin may be
partly caused by a breakdown in this
recovery system. Thus, the topical
application of LL-37, which not only
has antimicrobial activity but also
enhances Sema3A production, might
be a useful therapeutic strategy for AD.
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TO THE EDITOR
Leishmania major (L. major) parasites
cause skin lesions and are transmitted
by sand ﬂies infecting millions of people
each year. Upon infection, the parasites
(promastigotes) are phagocytosed by
macrophages where they transform
into amastigotes and replicate. The
amastigotes are eventually released
and taken up by dendritic cells (DCs),
which activate naive T cells in skin-
draining lymph nodes (sdLNs). In L.
major–infected humans and mice on a
resistant background, DCs induce an
IFNγ-driven T-helper (Th) type-1/T cyto-
toxic (Tc) 1 response that stimulatesAccepted article preview online 22 June 2015; published online 16 July 2015
Abbreviations: DC, dendritic cell; IFN, interferon; IL, interleukin; L. major, Leishmania major; sdLN, skin-
draining lymph node; Th, T helper; Treg, regulatory T cell
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